ArticlePLoS pathogens2026
Salmonella infection and biofilms drive anti-C1q and anti-dsDNA autoantibodies in systemic autoimmunity.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is characterized by autoantibody production alongside inflammatory manifestations, including nephritis. In SLE, infections are frequent and associated with disease flares, increasing morbidity and mortality. Additionally, dysbiosis, often marked by overgrowth of Pseudomonadota, is a prominent feature of SLE and lupus nephritis. We previously demonstrated that complexes of DNA and curli, an amyloidogenic protein from biofilms of Pseudomonadota, including Salmonella Typhimurium and E. coli, can induce anti-dsDNA and anti-chromatin autoantibody responses. Here, we assessed the effects of curli administration or Salmonella infection on autoimmune manifestations in wild-type and lupus-prone mice. A multiplex autoantibody assay showed increased levels of anti-C1q antibodies in curli-treated C57BL/6 and lupus-prone NZBxW/F1 mice compared to PBS-treated controls. An anti-C1q-specific ELISA confirmed the presence of anti-C1q antibodies in C57BL/6 mice after treatment with curli/DNA, extracted from E. coli or Salmonella biofilms, or infection with Salmonella. Prior to the onset of spontaneous disease, sera from young NZBxW/F1 mice, injected with curli, demonstrated increased anti-dsDNA and anti-C1q antibody responses compared to PBS-treated controls; however, no differences were found in older mice, post-onset, when autoantibody levels were already high. In MRL/lpr mice, curli treatment significantly exacerbated anti-C1q antibody production regardless of age and disease stage, compared to PBS-treated controls. While curli treatment did not significantly affect proteinuria in either model, curli-treatment of MRL/lpr mice significantly increased C1q deposition in glomeruli. This study uncovers a novel mechanism for the induction of anti-C1q autoantibodies and how infection or dysbiosis may exacerbate renal disease in SLE.
Indexed as
Identifiers
42821613What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.